A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens

Pinto, María Guadalupe Vizoso; Pfrepper, Klaus-Ingmar; Janke, Tobias; Noelting, Christina; Sander, Michaela; Lueking, Angelika; Haas, Juergen; Nitschko, Hans; Jaeger, Gundula; Baiker, Armin

doi:10.1186/1743-422x-7-165

Cited by 19 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For LuMPIS experiments 17 N-terminally tagged clones were made in pCR3.1NMBP and pCR3.1NeGFPluc 30 . Proteins Met, Plp, Pvx, X and Hel were expressed for thermophoresis experiments using pETGNMBP 55 . Domain sequences were defined as described recently 54 .…”

Section: Methodsmentioning

confidence: 99%

The Hepatitis E virus intraviral interactome

Osterman

Stellberger

Gebhardt

et al. 2015

Sci Rep

Self Cite

View full text Add to dashboard Cite

Hepatitis E virus (HEV) is an emerging virus causing epidemic acute hepatitis in developing countries as well as sporadic cases in industrialized countries. The life cycle of HEV is still poorly understood and the lack of efficient cell culture systems and animal models are the principal limitations for a detailed study of the viral replication cycle. Here we exhaustively examine all possible intraviral protein-protein interactions (PPIs) of HEV by systematic Yeast two-hybrid (Y2H) and LuMPIS screens, providing a basis for studying the function of these proteins in the viral replication cycle. Key PPIs correlate with the already published HEV 3D structure. Furthermore, we report 20 novel PPIs including the homodimerization of the RNA dependent RNA polymerase (RdRp), the self-interaction of the papain like protease, and ORF3 interactions with the papain-like protease and putative replicase components: RdRp, methylase and helicase. Furthermore, we determined the dissociation constant (Kd) of ORF3 interactions with the viral helicase, papain-like protease and methylase, which suggest a regulatory function for ORF3 in orchestrating the formation of the replicase complex. These interactions may represent new targets for antiviral drugs.

show abstract

Section: Methodsmentioning

confidence: 99%

The Hepatitis E virus intraviral interactome

Osterman

Stellberger

Gebhardt

et al. 2015

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Baseline EBV and HHV serologies of recipients and donors were obtained prior to transplantation surgery using accepted standard assays (10–15), which have shown reasonable sensitivity (range 93–100%) and specificity (range 91–100%), thus making cross‐reactivity between HHV and EBV proteins unlikely.…”

Section: Methodsmentioning

confidence: 99%

Risk factors for post‐transplant lymphoproliferative disease in patients with cystic fibrosis

Saueressig¹,

Boussaud²,

Amrein

et al. 2011

Clinical Transplantation

View full text Add to dashboard Cite

The objective of this study was to retrospectively analyze risk factors associated with post-transplant lymphoproliferative disease (PTLD) in a cohort of 112 lung transplant recipients with cystic fibrosis (CF). Prior to transplantation, patients were tested for Epstein-Barr virus (EBV), human herpesvirus (HHV types 1, 2, 3, 6, and 8), herpes zoster virus, and cytomegalovirus (CMV) serologies. PTLD diagnosis was established based on increased EBV viral charge plus clinical/radiographic findings and confirmed by biopsy. Negative EBV and HHV serologies at the time of lung transplantation (LTx) were significant risk factors associated with development of PTLD in patients with CF in the univariate logistic regression analysis (p < 0.05) and also in the multivariate analysis (odds ratio of 77.5 and 12.5, respectively). CMV serology, CMV mismatch, acute rejection in the first three months following LTx, HLA-A3 antigen expression, and female gender did not affect PTLD. Our study confirmed the presence of a strong association between negative EBV serology at the time of LTx and PTLD and suggested an independent effect of negative HHV serology on PTLD.

show abstract

“…Antibody tests for VZV include the fluorescent antibody to membrane antigen (FAMA), enzyme immunoassay, and enzyme-linked immunosorbent assays (ELISA). These tests use whole antigens of the virus or antigen extracted from VZV-infected cell cultures, whereas other tests use the external glycoproteins [glycoprotein E (gE), gB, and gH] as antigens, such as the gpELISA ( 35 ). FAMA is highly sensitive and considered the gold standard test for VZV antibodies, but is labor intensive and not automated ( 36 ).…”

Section: Diagnosismentioning

confidence: 99%

“…Combination of serology testing and real-time PCR on paired serum and CSF/intraocular fluid can be used for diagnosing HZ with cerebral and ocular complications ( 38 ). It is important to develop new precise assays because false-negative and false-positive results due to limitations of serologic testing may lead to unnecessary vaccinations or therapy ( 35 ). Even more important is the limitation that antibody titers do not necessarily correlate with protection.…”

Section: Diagnosismentioning

confidence: 99%

Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature

et al. 2018

View full text Add to dashboard Cite

This narrative review focuses on the herpes zoster (HZ) and its prevention in transplant patients. Varicella zoster virus (VZV) is highly contagious and distributed worldwide in humans. Primary VZV infection usually causes varicella and then establishes a lifelong latency in dorsal root ganglia. Reactivation of VZV leads to HZ and related complications such as postherpetic neuralgia. Age and decreased immunity against VZV are important risk factors for developing HZ. Transplant patients are at increased risk for developing HZ and related complications due to their immunocompromised status and the need for lifetime immunosuppression. Diagnosis of HZ in transplant patients is often clinically difficult, and VZV-specific antibodies should be determined by serologic testing to document prior exposure to VZV during their pre-transplant evaluation process. Although antiviral agents are available, vaccination should be recommended for preventing HZ in transplant patients considering their complicated condition and weak organ function. Currently, there are two licensed HZ vaccines, of which one is a live-attenuated vaccine and the other is a HZ subunit vaccine. Both vaccines have shown promising safety and efficacy in transplants patients and especially the subunit vaccine could be administered post-transplant since this vaccine does not contain any live virus. Larger studies are needed about safety and immunogenicity of HZ vaccines in transplant populations, and extra efforts are needed to increase vaccine usage according to guidelines.

show abstract

A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens

Cited by 19 publications

References 31 publications

The Hepatitis E virus intraviral interactome

The Hepatitis E virus intraviral interactome

Risk factors for post‐transplant lymphoproliferative disease in patients with cystic fibrosis

Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature

Contact Info

Product

Resources

About